CARGO Therapeutics, Inc. (NASDAQ:CRGX – Get Free Report) CFO Anup Radhakrishnan sold 1,600 shares of the business’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $25.28, for a total transaction of $40,448.00. Following the sale, the chief financial officer now directly owns 6,446 shares in the company, valued at approximately $162,954.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
CARGO Therapeutics Trading Down 4.6 %
Shares of NASDAQ:CRGX opened at $23.85 on Monday. The firm’s fifty day moving average is $18.09 and its 200-day moving average is $19.43. CARGO Therapeutics, Inc. has a 52 week low of $13.14 and a 52 week high of $33.92.
CARGO Therapeutics (NASDAQ:CRGX – Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($1.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.04. As a group, equities analysts expect that CARGO Therapeutics, Inc. will post -4.37 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on CRGX
Hedge Funds Weigh In On CARGO Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. acquired a new position in CARGO Therapeutics in the first quarter valued at $48,000. American International Group Inc. acquired a new position in CARGO Therapeutics in the first quarter valued at $237,000. BNP Paribas Financial Markets acquired a new position in CARGO Therapeutics in the first quarter valued at $238,000. California State Teachers Retirement System acquired a new position in CARGO Therapeutics in the first quarter valued at $337,000. Finally, Swiss National Bank acquired a new position in CARGO Therapeutics in the first quarter valued at $636,000. Institutional investors and hedge funds own 93.16% of the company’s stock.
CARGO Therapeutics Company Profile
CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
See Also
- Five stocks we like better than CARGO Therapeutics
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- NYSE Stocks Give Investors a Variety of Quality Options
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- How to Use High Beta Stocks to Maximize Your Investing Profits
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for CARGO Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CARGO Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.